arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Organon & Co.

OGN
$13.79 ▼ -0.06 (-0.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Neutral
auto_awesome

Analytical Summary

Organon & Co. shows mixed fundamentals. However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $3.6B
Dividend Yield 0.15%
Revenue Growth -1.7% ↗
Op. Margin —
ROIC —
FCF / Share $1.24 ↗
Trailing P/E 22.2x
Price / Book 3.0x
FCF Yield 9.0%
Debt / Equity 7.17
info Valuation on last close. End-of-day price, Nov 5, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.57B
↓ -1.7% —
Net Income Profit after all expenses
$164.00M
↑ +2.5% —
FCF / Share Free cash flow per share
$1.24
↑ +401.5% —
Long-Term Debt Long-term obligations
$8.55B
— 0.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
49
Returns ↓
90
Financial Health
2
Cash Quality ↑
91

Dividend History

Dividend / share · sourced from SEC filings
$0.34 Latest / share
-69.6% YoY
-11.7% 5-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 29 quarters